Date published: 2026-2-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

PLC-XD1 Inhibitors

Phosphatidylinositol specific phospholipase C X domain containing 1 (PLC-XD1) is a member of the phospholipase C family, enzymes pivotal to intracellular signaling pathways. These enzymes typically function by hydrolyzing phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol trisphosphate (IP3). The subsequent surge in DAG and IP3 levels inside cells triggers a cascade of events, notably calcium release and activation of protein kinase C, that contribute to various cellular responses. PLC-XD1's exact role and distinctions from other phospholipase C isoforms remains an area ripe for exploration, but its position within such a crucial biochemical pathway signifies its potential importance in cellular communication and response mechanisms.

The realm of PLC-XD1 inhibitors encompasses a collection of chemical compounds specifically tailored to dampen or entirely block the functional aspects of PLC-XD1. Given the broader context of the phospholipase C family, potential inhibitors might act by hindering the enzyme's capacity to bind its substrates, by obstructing its catalytic sites, or by influencing its conformation to a non-active state. Further, at the genetic level, certain compounds could curtail the transcription or translation of the PLC-XD1 gene, thereby reducing its expression in cells. While the precise mechanisms would necessitate rigorous experimentation, the study of PLC-XD1 inhibitors presents a tantalizing avenue for researchers aiming to dissect the nuances of intracellular signaling, particularly within the framework of phospholipase C mediated responses. As these inhibitors get developed and studied, they will undoubtedly shed light on the intricacies of PLC-XD1 and its implications in cell biology.

SEE ALSO...

Items 1 to 10 of 20 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

PMA

16561-29-8sc-3576
sc-3576A
sc-3576B
sc-3576C
sc-3576D
1 mg
5 mg
10 mg
25 mg
100 mg
$41.00
$132.00
$214.00
$500.00
$948.00
119
(6)

PMA activates protein kinase C (PKC), which can phosphorylate and activate PLC-XD1, enhancing its activity.

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$74.00
$243.00
$731.00
$2572.00
$21848.00
53
(3)

Actinomycin D might bind to DNA regions associated with the PLC-XD1 gene, potentially obstructing its transcription into RNA.

Cycloheximide

66-81-9sc-3508B
sc-3508
sc-3508A
100 mg
1 g
5 g
$41.00
$84.00
$275.00
127
(6)

This compound could selectively hinder the translation of PLC-XD1 mRNA, thereby reducing its protein output.

Ionomycin

56092-82-1sc-3592
sc-3592A
1 mg
5 mg
$78.00
$270.00
80
(4)

Ionomycin increases intracellular calcium levels, potentially enhancing PLC-XD1 activity through calcium-dependent mechanisms.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

By modifying the methylation patterns of genes, 5-Azacytidine could affect the transcription of the PLC-XD1 gene.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$152.00
$479.00
$632.00
$1223.00
$2132.00
33
(3)

By inhibiting histone deacetylase, this compound may alter chromatin structure around the PLC-XD1 gene, possibly suppressing its expression.

Forskolin

66575-29-9sc-3562
sc-3562A
sc-3562B
sc-3562C
sc-3562D
5 mg
50 mg
1 g
2 g
5 g
$78.00
$153.00
$740.00
$1413.00
$2091.00
73
(3)

Forskolin raises cAMP levels, which may lead to the activation of a PKA-dependent pathway enhancing PLC-XD1 activity.

Guanosine 5′-O-(3-thiotriphosphate) tetralithium salt

94825-44-2sc-202639
10 mg
$465.00
(0)

GTPγS is a non-hydrolyzable GTP analog that can activate G-proteins, potentially leading to the activation of PLC-XD1.

α-Amanitin

23109-05-9sc-202440
sc-202440A
1 mg
5 mg
$269.00
$1050.00
26
(2)

This compound could block RNA polymerase II, hindering the transcription of PLC-XD1 mRNA.

Lithium

7439-93-2sc-252954
50 g
$214.00
(0)

Lithium inhibits inositol monophosphatase leading to higher inositol triphosphate (IP3) levels, possibly enhancing PLC-XD1 function.